We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
AbbVie (ABBV - Free Report) closed at $284.80 in the latest trading session, marking a -1.48% move from the prior day. This move lagged the S&P 500's daily gain of 0.58%. At the same time, the Dow added 0.69%, and the tech-heavy Nasdaq gained 1.05%.
Coming into today, shares of the drugmaker had gained 9% in the past month. In that same time, the Medical sector gained 3.5%, while the S&P 500 gained 0.97%.
The investment community will be closely monitoring the performance of AbbVie in its forthcoming earnings report. The company is scheduled to release its earnings on October 30, 2026. In that report, analysts expect AbbVie to post earnings of $3.79 per share. This would mark year-over-year growth of 103.76%. Simultaneously, our latest consensus estimate expects the revenue to be $17.37 billion, showing a 10.1% escalation compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $13.97 per share and a revenue of $67.64 billion, representing changes of +39.7% and +10.59%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for AbbVie. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.81% lower within the past month. AbbVie is currently a Zacks Rank #4 (Sell).
Investors should also note AbbVie's current valuation metrics, including its Forward P/E ratio of 20.69. This represents a premium compared to its industry average Forward P/E of 17.25.
Investors should also note that ABBV has a PEG ratio of 1.32 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.04 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 219, positioning it in the bottom 11% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
AbbVie (ABBV - Free Report) closed at $284.80 in the latest trading session, marking a -1.48% move from the prior day. This move lagged the S&P 500's daily gain of 0.58%. At the same time, the Dow added 0.69%, and the tech-heavy Nasdaq gained 1.05%.
Coming into today, shares of the drugmaker had gained 9% in the past month. In that same time, the Medical sector gained 3.5%, while the S&P 500 gained 0.97%.
The investment community will be closely monitoring the performance of AbbVie in its forthcoming earnings report. The company is scheduled to release its earnings on October 30, 2026. In that report, analysts expect AbbVie to post earnings of $3.79 per share. This would mark year-over-year growth of 103.76%. Simultaneously, our latest consensus estimate expects the revenue to be $17.37 billion, showing a 10.1% escalation compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $13.97 per share and a revenue of $67.64 billion, representing changes of +39.7% and +10.59%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for AbbVie. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.81% lower within the past month. AbbVie is currently a Zacks Rank #4 (Sell).
Investors should also note AbbVie's current valuation metrics, including its Forward P/E ratio of 20.69. This represents a premium compared to its industry average Forward P/E of 17.25.
Investors should also note that ABBV has a PEG ratio of 1.32 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.04 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 219, positioning it in the bottom 11% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.